Compare FISN & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FISN | SLS |
|---|---|---|
| Founded | N/A | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 386.4M | 924.5M |
| IPO Year | 2025 | 2007 |
| Metric | FISN | SLS |
|---|---|---|
| Price | $6.53 | $13.41 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 203.9K | ★ 6.4M |
| Earning Date | N/A | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 98.25 | 50.00 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $110.98 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.76 | $1.39 |
| 52 Week High | $15.50 | $15.88 |
| Indicator | FISN | SLS |
|---|---|---|
| Relative Strength Index (RSI) | 33.79 | 55.17 |
| Support Level | N/A | $11.43 |
| Resistance Level | $9.05 | $15.77 |
| Average True Range (ATR) | 0.62 | 1.19 |
| MACD | -0.06 | 0.14 |
| Stochastic Oscillator | 9.17 | 62.22 |
Deep Fission Inc is a nuclear energy technology company developing a small modular reactor based on established pressurized water reactor technology, with novel emplacement in deep boreholes approximately one mile below the Earth's surface. Its reactor, which is referred to as the Gravity Reactor, will leverage subsurface conditions to support key containment and operating functions, including the use of hydrostatic pressure from a water column within the borehole to support reactor operating pressure and cooling, and the surrounding geological formation to provide structural confinement and shielding. The group's focus is within the United States, where electricity demand growth, expanding digital infrastructure, and evolving energy policy.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.